PAP
Persistent Asset Partners Portfolio holdings
AUM
$114M
This Quarter Return
+1.61%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$117M
AUM Growth
–
Cap. Flow
+$117M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
43.37%
Holding
124
New
96
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Humana
HUM
|
$11.2M |
| 2 |
DaVita
DVA
|
$7.6M |
| 3 |
UnitedHealth
UNH
|
$6.41M |
| 4 |
Pennant Group
PNTG
|
$4.37M |
| 5 |
Cardinal Health
CAH
|
$4.18M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 70% |
| 2 | Financials | 24.42% |
| 3 | Energy | 2.02% |
| 4 | Materials | 1.9% |
| 5 | Consumer Discretionary | 1.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Equinox Gold
EQX
$7.12B
| $346K | 0.29% |
+57,072
| New | +$346K |
|
77
First Western Financial
MYFW
$218M
| $307K | 0.25% |
+14,538
| New | +$307K |
|
78
Reviva Pharmaceuticals
RVPH
$31.3M
| $305K | 0.25% |
+161,170
| New | +$305K |
|
79
Arcutis Biotherapeutics
ARQT
$1.91B
| $302K | 0.25% |
+22,810
| New | +$302K |
|
|
CLYM
80
Climb Bio, Inc. Common Stock
CLYM
$165M
| $277K | 0.23% |
+145,760
| New | +$277K |
|
81
Evolus
EOLS
$477M
| $266K | 0.22% |
+19,054
| New | +$266K |
|
82
89bio
ETNB
$1.37B
| $258K | 0.21% |
+26,842
| New | +$258K |
|
83
Vir Biotechnology
VIR
$765M
| $250K | 0.21% |
+24,069
| New | +$250K |
|
84
Esquire Financial Holdings
ESQ
$814M
| $250K | 0.21% |
+2,797
| New | +$250K |
|
85
Rocket Companies
RKT
$37.6B
| $157K | 0.13% |
+12,426
| New | +$157K |
|
86
Nektar Therapeutics
NKTR
$543M
| $138K | 0.11% |
+11,105
| New | +$138K |
|
|
SLSR
87
Solaris Resources
SLSR
$880M
| $134K | 0.11% |
+41,812
| New | +$134K |
|
88
Zevra Therapeutics
ZVRA
$501M
| $101K | 0.08% |
+12,831
| New | +$101K |
|
89
Oric Pharmaceuticals
ORIC
$1.03B
| $76.8K | 0.06% |
+7,373
| New | +$76.8K |
|
90
Eledon Pharmaceuticals
ELDN
$155M
| $67.1K | 0.06% |
+14,855
| New | +$67.1K |
|
91
Gossamer Bio
GOSS
$587M
| $65.5K | 0.05% |
+65,894
| New | +$65.5K |
|
92
Terns Pharmaceuticals
TERN
$651M
| $57.1K | 0.05% |
+12,807
| New | +$57.1K |
|
93
Candel Therapeutics
CADL
$281M
| $42.7K | 0.04% |
+6,046
| New | +$42.7K |
|
|
MODV
94
DELISTED
ModivCare
MODV
| $35K | 0.03% |
+8,757
| New | +$35K |
|
|
CMRX
95
DELISTED
Chimerix, Inc.
CMRX
| $34.7K | 0.03% |
+8,813
| New | +$34.7K |
|
96
Q32 Bio
QTTB
$20.9M
| $18.2K | 0.02% |
+6,019
| New | +$18.2K |
|
97
Affirm
AFRM
$27.8B
| – | – |
0
| – | – |
|
98
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
0
| – | – |
|
99
Altimmune
ALT
$325M
| – | – |
0
| – | – |
|
100
ALX Oncology
ALXO
$54.6M
| – | – |
0
| – | – |
|